ReviewBlood reviews2021
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system.
Review in Blood reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 7 syntheses or guidelines pooled it, 209 citations in OpenAlex.
- Vascular Complications of Long COVID-From Endothelial Dysfunction to Systemic Thrombosis: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- Pooled it
- Tracheostomy outcomes in critically ill patients with COVID-19: a systematic review, meta-analysis, and meta-regression.British journal of anaesthesia · 2022Pooled it
- Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.Frontiers in medicine · 2022Pooled it
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.Journal for immunotherapy of cancer · 2021Pooled it
- D-Dimer in Viral Respiratory Infections: Established Evidence in COVID-19 and Emerging Evidence in Other Respiratory Viruses.International journal of molecular sciences · 2026Review
- Altered Endocannabinoid Signaling in Placentas from SARS-CoV-2-Infected Pregnancies.Diagnostics (Basel, Switzerland) · 2026Article
- Admission D-Dimer for Early Risk Stratification of in-Hospital Mortality in Adults with Non-HIV Cryptococcal Meningitis: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Association of foveal avascular zone (FAZ) enlargement with SARS-CoV-2 infection and long COVID-19.BMC ophthalmology · 2025Article
- Evaluation of short and long-term laboratory and instrumental findings in COVID-19 patients hospitalized in Tuscany.World journal of experimental medicine · 2025Article
- Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies.Microorganisms · 2025Review
- Risk factors and outcome of extracorporeal cardiopulmonary resuscitation patients with out-of-hospital cardiac arrest and in-hospital cardiac arrest: a nationwide prospective and observational study of 939 hospitals in China.BMC emergency medicine · 2025Observational
- Correlation between virological response and portal vein thrombosis in patients with chronic hepatitis B.Scientific reports · 2025Article
- Article
- Low vitamin K status is a potential risk factor for COVID-19 infected patients: a systematic review and meta-analysis.Frontiers in nutrition · 2025Review
- Influenza A (H1N1) and COVID-19 Pneumonias: An Evaluation in the Light of New Hematologic Indices.Journal of inflammation research · 2025Article
- Co-infections exacerbate inflammatory responses in COVID-19 patients, promoting coagulopathy and myocardial injury, leading to increased disease severity.Frontiers in immunology · 2025Article
- Treatment with intravenous immunoglobulin modulates coagulation- and complement-related pathways in COVID-19 patients.Frontiers in immunology · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a new pandemic, caused by Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-Cov2) infection and characterized by a broad spectrum of clinical manifestations. Inflammation and the innate immune system have been recently recognized as pivotal players in the most severe forms, characterized by significantly elevated levels of pro-inflammatory cytokines. In this setting, several studies have also reported the presence of abnormalities in coagulation parameters and platelets count, possibly identifying a subgroup of patients with poor prognosis. Some reports of full-blown thromboembolic events are emerging. Among the possible mechanisms underlying coagulation dysfunction, the so-called "cytokine storm" seems to play a pivotal role. Other candidate factors include virus-specific mechanisms, related to the virus interaction with renin angiotensin system (RAS) and the fibrinolytic pathway, but also comorbidities affecting these patients. Coagulation dysfunction is therefore a candidate risk factor for adverse outcomes in COVID-19 and should be carefully addressed in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.